OBJECTIVES: Despite lithium's clinical efficacy in treating mania in bipolar disorder (BD), studies evaluating early improvement and subsequent treatment response are sparse. This study investigated whether early improvement (within one week) to lithium monotherapy predicted later response and remission in individuals with BD mania. METHODS: BD-I patients (n=46) experiencing a manic episode received lithium monotherapy for four weeks (initial dose: 600mg/d, adjusted to therapeutic levels); individuals experiencing a mixed episode, rapid cyclers, previous non-responders to lithium, and those with current drug abuse/dependence were excluded. Symptoms were rated using the Young Mania Rating Scale (YMRS) at baseline and at Days 7, 14, 21, and 28. RESULTS: Thirty-three percent of the total sample responded to lithium within the first week of treatment, defined as a ≥50% decrease from baseline YMRS scores; 63% responded by study endpoint. In addition, 39% of the total sample showed early improvement (at least 20% decrease in YMRS scores) after one week of treatment. In this group, 79% responded to lithium by study endpoint. Among those showing less than 20% improvement at Week 1, only 23% responded to lithium by study endpoint. LIMITATIONS: History of episodes sequence was not assessed. CONCLUSIONS: Early improvement in response to lithium monotherapy in subjects with BD mania predicted later response and remission. Most patients who did not show early improvement in response to lithium during the first week of treatment showed no response after one month. The findings provide a valuable clinical tool for early identification of those patients most likely to benefit from lithium in clinical practice.
OBJECTIVES: Despite lithium's clinical efficacy in treating mania in bipolar disorder (BD), studies evaluating early improvement and subsequent treatment response are sparse. This study investigated whether early improvement (within one week) to lithium monotherapy predicted later response and remission in individuals with BD mania. METHODS: BD-I patients (n=46) experiencing a manic episode received lithium monotherapy for four weeks (initial dose: 600mg/d, adjusted to therapeutic levels); individuals experiencing a mixed episode, rapid cyclers, previous non-responders to lithium, and those with current drug abuse/dependence were excluded. Symptoms were rated using the Young Mania Rating Scale (YMRS) at baseline and at Days 7, 14, 21, and 28. RESULTS: Thirty-three percent of the total sample responded to lithium within the first week of treatment, defined as a ≥50% decrease from baseline YMRS scores; 63% responded by study endpoint. In addition, 39% of the total sample showed early improvement (at least 20% decrease in YMRS scores) after one week of treatment. In this group, 79% responded to lithium by study endpoint. Among those showing less than 20% improvement at Week 1, only 23% responded to lithium by study endpoint. LIMITATIONS: History of episodes sequence was not assessed. CONCLUSIONS: Early improvement in response to lithium monotherapy in subjects with BD mania predicted later response and remission. Most patients who did not show early improvement in response to lithium during the first week of treatment showed no response after one month. The findings provide a valuable clinical tool for early identification of those patients most likely to benefit from lithium in clinical practice.
Authors: Mauricio Tohen; Michael Case; Madhukar H Trivedi; Michael E Thase; Scott J Burke; Todd M Durell Journal: J Clin Psychiatry Date: 2010-02-23 Impact factor: 4.384
Authors: Trisha Suppes; Ellen B Dennehy; Robert M A Hirschfeld; Lori L Altshuler; Charles L Bowden; Joseph R Calabrese; M Lynn Crismon; Terence A Ketter; Gary S Sachs; Alan C Swann Journal: J Clin Psychiatry Date: 2005-07 Impact factor: 4.384
Authors: John P Houston; Terence A Ketter; Michael Case; Charles Bowden; Elisabeth K Degenhardt; Hassan H Jamal; Mauricio Tohen Journal: J Psychiatr Res Date: 2010-06-11 Impact factor: 4.791
Authors: Terence A Ketter; Ofer Agid; Shitij Kapur; Antony Loebel; Cynthia O Siu; Steven J Romano Journal: J Psychiatr Res Date: 2009-08-21 Impact factor: 4.791
Authors: Rodrigo Machado-Vieira; Jair C Soares; Diogo R Lara; David A Luckenbaugh; João V Busnello; Getulio Marca; Angelo Cunha; Diogo O Souza; Carlos A Zarate; Flavio Kapczinski Journal: J Clin Psychiatry Date: 2008-08 Impact factor: 4.384
Authors: Lakshmi N Yatham; Sidney H Kennedy; Ayal Schaffer; Sagar V Parikh; Serge Beaulieu; Claire O'Donovan; Glenda MacQueen; Roger S McIntyre; Verinder Sharma; Arun Ravindran; L Trevor Young; Allan H Young; Martin Alda; Roumen Milev; Eduard Vieta; Joseph R Calabrese; Michael Berk; Kyooseob Ha; Flávio Kapczinski Journal: Bipolar Disord Date: 2009-05 Impact factor: 6.744
Authors: Armin Szegedi; Wim T Jansen; Arjen P P van Willigenburg; Egbert van der Meulen; Hans H Stassen; Michael E Thase Journal: J Clin Psychiatry Date: 2009-02-24 Impact factor: 4.384
Authors: Du Lei; Wenbin Li; Kun Qin; Yuan Ai; Maxwell J Tallman; L Rodrigo Patino; Jeffrey A Welge; Thomas J Blom; Christina C Klein; David E Fleck; Qiyong Gong; Caleb M Adler; Jeffrey R Strawn; John A Sweeney; Melissa P DelBello Journal: Neuropsychopharmacology Date: 2022-10-13 Impact factor: 8.294
Authors: Klaus Oliver Schubert; Anbupalam Thalamuthu; Azmeraw T Amare; Joseph Frank; Fabian Streit; Mazda Adl; Nirmala Akula; Kazufumi Akiyama; Raffaella Ardau; Bárbara Arias; Jean-Michel Aubry; Lena Backlund; Abesh Kumar Bhattacharjee; Frank Bellivier; Antonio Benabarre; Susanne Bengesser; Joanna M Biernacka; Armin Birner; Cynthia Marie-Claire; Micah Cearns; Pablo Cervantes; Hsi-Chung Chen; Caterina Chillotti; Sven Cichon; Scott R Clark; Cristiana Cruceanu; Piotr M Czerski; Nina Dalkner; Alexandre Dayer; Franziska Degenhardt; Maria Del Zompo; J Raymond DePaulo; Bruno Étain; Peter Falkai; Andreas J Forstner; Louise Frisen; Mark A Frye; Janice M Fullerton; Sébastien Gard; Julie S Garnham; Fernando S Goes; Maria Grigoroiu-Serbanescu; Paul Grof; Ryota Hashimoto; Joanna Hauser; Urs Heilbronner; Stefan Herms; Per Hoffmann; Liping Hou; Yi-Hsiang Hsu; Stephane Jamain; Esther Jiménez; Jean-Pierre Kahn; Layla Kassem; Po-Hsiu Kuo; Tadafumi Kato; John Kelsoe; Sarah Kittel-Schneider; Ewa Ferensztajn-Rochowiak; Barbara König; Ichiro Kusumi; Gonzalo Laje; Mikael Landén; Catharina Lavebratt; Marion Leboyer; Susan G Leckband; Mario Maj; Mirko Manchia; Lina Martinsson; Michael J McCarthy; Susan McElroy; Francesc Colom; Marina Mitjans; Francis M Mondimore; Palmiero Monteleone; Caroline M Nievergelt; Markus M Nöthen; Tomas Novák; Claire O'Donovan; Norio Ozaki; Urban Ösby; Sergi Papiol; Andrea Pfennig; Claudia Pisanu; James B Potash; Andreas Reif; Eva Reininghaus; Guy A Rouleau; Janusz K Rybakowski; Martin Schalling; Peter R Schofield; Barbara W Schweizer; Giovanni Severino; Tatyana Shekhtman; Paul D Shilling; Katzutaka Shimoda; Christian Simhandl; Claire M Slaney; Alessio Squassina; Thomas Stamm; Pavla Stopkova; Fasil Tekola-Ayele; Alfonso Tortorella; Gustavo Turecki; Julia Veeh; Eduard Vieta; Stephanie H Witt; Gloria Roberts; Peter P Zandi; Martin Alda; Michael Bauer; Francis J McMahon; Philip B Mitchell; Thomas G Schulze; Marcella Rietschel; Bernhard T Baune Journal: Transl Psychiatry Date: 2021-11-29 Impact factor: 7.989